ActRight

The growing number of patent expiration of various blockbuster biologic drugs is primarily driving the GCC biosimilar market. Moreover, the expanding geriatric population and the increasing prevalence of chronic disorders, such as autoimmune diseases, cancer, diabetes, etc., are also contributing to the market growth. In addition to this, the escalating adoption of biosimilars, owing to their economical prices, is acting as another significant growth-inducing factor.